Centrum 7/6  banner

David Nicholson

Allergan readies launch of Rhofade rosacea cream

Allergan readies launch of Rhofade rosacea cream

DUBLIN, Ireland — Allergan plc is set to release Rhofade oxymetazoline hydrochloride cream 1%, a topical medication to help treat rosacea. Indicated for persistent facial erythema, or redness, associated with rosacea in adults, Rhofade adds brings a once-daily solution to the few alternatives available for the treatment of this rosacea symptom, Allergan said. Plans call

Allergan to acquire Vitae Pharmaceuticals

Allergan to acquire Vitae Pharmaceuticals

DUBLIN, Ireland — Allergan plc plans to buy clinical-stage biotech firm Vitae Pharmaceuticals Inc. in a cash deal valued at $639 million. Allergan said the acquisition will bolster its dermatology product pipeline with the addition of VTP-43742, a Phase 2 orally active RORγt inhibitor for the potential treatment of psoriasis and other autoimmune disorders. The

Allergan partners with Bosworth to launch Aczone Gel

Allergan partners with Bosworth to launch Aczone Gel

DUBLIN, Ireland — Allergan plc has teamed up with actress and model Kate Bosworth to launch Aczone Gel 7.5%, a new prescription topical treatment for acne. Also on Monday, Allergan said it has received Food and Drug Administration approval for Byvalson tablets (nebivolol 5 mg/valsartan 80 mg), a hypertension treatment that the company called the

PP_1170x120_10-25-21